Limitations, agreements, and source contact

Daratumumab, Azacitidine, and Dexamethasone for Treatment of Patients With Recurrent or Refractory Multiple Myeloma Previously Treated With Daratumumab · Source last updated 2024-04-30

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement

pi Sponsor Employee

true

limitations And Caveats

description

The study was closed to enrollment earlier than expected due to slow enrollment and change in sponsor research direction.

point Of Contact

email

Alfred.Chung@ucsf.edu

organization

University of California, San Francisco

phone

(415) 353-2421

title

Dr. Alfred Chung

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice